Tirzepatide
Dual-agonist incretin research peptide acting at the GLP-1 and GIP receptors. Lyophilized powder, batch-tested by HPLC.
Lot TZ-2605 tested at 99.20% by HPLC (RP-HPLC / HPLC-RTM). Certificate COA-2026-9422, issued 2026-07-02 by Titreon Analytical.
Read the certificateDownload the PDFWhat Tirzepatide is
Tirzepatide is a dual-agonist incretin research peptide acting at the GLP-1 and GIP receptors. The published literature describes effects on gastric emptying, glucose-dependent insulin response and central appetite signalling, with an additional GIP contribution in adipose tissue. Supplied as a lyophilized powder for laboratory and in-vitro research use.
Specifications
- CAS
- 2023788-19-2
- Formula
- C₂₂₅H₃₄₈N₄₈O₆₈
- MW
- 4813.45 g/mol
Laboratory research use only. Not for human or animal consumption. This product is supplied as a chemical reference compound for controlled in-vitro and laboratory research. It is not a drug, food, cosmetic or medical device, and it has not been evaluated by the FDA for safety or efficacy.
Product information is published for educational and documentation purposes. It describes what the compound is and what published research reports. It is not medical advice, not a recommendation that any person use any compound, and not instructions for use in humans. See the full research disclaimer.